Guillain–Barré syndrome

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego

Retrieved on: 
Tuesday, January 16, 2024
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Protein, Streptococcus pyogenes, Multimedia, Half-life, Immunoglobulin G, Autoimmune disease, WT, Disease, Rabbit, Antibody, MHC, Ides, Immunity, Guillain–Barré syndrome, Vaccine

The presentation will take place at the 23rd annual PepTalk conference in San Diego.

Key Points: 
  • The presentation will take place at the 23rd annual PepTalk conference in San Diego.
  • The IgG-degrading enzyme of S. pyogenes (IdeS) has been approved in wild type form for use in certain kidney transplantation recipients, where IgG depletion successfully mitigates host immunity against the transplant.
  • View the full release here: https://www.businesswire.com/news/home/20240116136157/en/
    Figure shows IgG levels after WT IdeS in diamonds and Cyrus’ candidates in squares and triangles.
  • Indications such as Guillain-Barre Syndrome, Autoimmune Immune Thrombocytopenia, Idiopathic Immune Myopathies, pemphigus vulgaris, and other diseases with a poor current standard of care are under consideration.

EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001

Retrieved on: 
Monday, December 4, 2023
Guillain–Barré syndrome, Infection, Inflammatory bowel disease, CMO, Multiple sclerosis, Vaccine, Disease, Virus-like particle, Mouse, Human, GMP, EBV, Cancer, Epithelium, CSO, Chronic fatigue syndrome, Epstein–Barr virus, Infectious mononucleosis

The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.

Key Points: 
  • The presented data demonstrate that even at low concentrations, non-adjuvanted EBV-001 induces a specific and strong B cell response in mice.
  • EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate.
  • “In addition to a strong preclinical data package, we now have everything in place for the start of clinical trials,” said Axel Polack, M.D., designated CEO of EBViously.
  • It is also known that people infected with EBV are 32 times more likely to develop multiple sclerosis.

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Retrieved on: 
Monday, October 9, 2023
ADA, Incidence, Antibody, Food, Autoimmunity, Aes, BLA, Therapy, Data, Safety, DRESS, FDA, Flare, Immunoglobulin G, MENA, Immune system, SAN, Patient, Guillain–Barré syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GPP, Erythema, Inflammation, Infection, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, EU

Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab.

Key Points: 
  • Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab.
  • “The success of the GEMINI-1 trial highlights Anaptys’ commitment to patients and our ability to internally discover and develop differentiated antibodies,” said Daniel Faga, president and chief executive officer of Anaptys.
  • The registration-enabling GEMINI-1 trial in GPP, which recruited 45 patients, is the first randomized, double-blind, placebo-controlled trial to use the composite endpoint of Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) at Week 4 as its primary assessment.
  • Patients were randomized 1:1:1 to receive a single infusion of 750mg IV imsidolimab, 300mg IV imsidolimab or placebo at Day 0.

Global Central Nervous System Partnering 2023: Information on Every Deal Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 12, 2023
Health, Biotechnology, Chapter Four, Influenza B virus, Central nervous system, Disease, Traumatic brain injury, Sympathetic nervous system, TB, Dizziness, A-Z, Stroke, Research, Directory, Weakness, Orientation, Headache, CNS, Chapter Three, Multiple sclerosis, Vertigo, Chapter One, Restless, Migraine, Chapter Two, Chapter Five, Chapter Six, Collection, Guillain–Barré syndrome, Peripheral neuropathy, Creutzfeldt–Jakob disease, Parkinson's disease, Amyotrophy, Spinal cord, ALS, Cerebral palsy, Hyperlink, Bacteria, Restless legs syndrome, Mycobacterium tuberculosis, Pharmaceutical industry, Music, Bank, Drug, Cryptocurrency, Medical device, Nausea, Haemophilus, Epilepsy, Pain, Neuralgia, Fibromyalgia, Paralysis, Stuttering, Meningitis

Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.

Key Points: 
  • Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
  • The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
  • Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016.
  • Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.

GeoVax Receives Notice of Allowance for Zika Vaccine Patent

Retrieved on: 
Wednesday, January 25, 2023
Antibody, Disease, Infection, Biotechnology, Rest, Zika virus, COVID-19, Cancer, Guillain–Barré syndrome, Neurodegeneration, Vaccine, Risk, Pregnancy, Dengue fever, Vaccination, Microcephaly, Tick-borne encephalitis, Patient, Patent, GeoVax, NS1, Flavivirus, Paracetamol, MVA, Woman, Yellow fever, ADE, Flaviviridae, ZIKV

ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.”

Key Points: 
  • ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No.
  • 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.”
    “Our novel Zika vaccine candidate, GEO-ZM02, is constructed using our modified vaccinia Ankara (MVA) vector platform.
  • Preclinical studies demonstrated a single dose of GEO-ZM02 provided 100% protection against a lethal dose of Zika virus,” stated GeoVax CEO David Dodd.
  • The claims to be granted in the patent cover GeoVax’s MVA vector comprising a nucleic acid sequence encoding a ZIKV nonstructural (NS1) protein, of which GEO-ZM02 is designed.

Intravenous Immunoglobulin Global Market Report 2022: Rising Prevalence of Immunodeficiency Diseases Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Infectious Diseases, Pharmaceutical, Health, Immunodeficiency, National Institute, Immunoglobulin D, Industry, European Federation of Pharmaceutical Industries and Associations, Guillain–Barré syndrome, EFPIA, Prevalence, Hypogammaglobulinemia, Pharmacy, Infection, Immunoglobulin G, Immunoglobulin M, India Brand Equity Foundation, Chiapas, CAGR, Patient, Hospital, Purpura, Consumer, NIAID, Investment, Federalisation of the European Union, Myasthenia gravis, Immunoglobulin E, Immunoglobulin therapy, National Institute of Allergy and Infectious Diseases, Radiation therapy, Myopathy, Immunoglobulin A, Vaccination, Multifocal motor neuropathy, FDA, Chronic inflammatory demyelinating polyneuropathy, Vaccine, Fine chemical

Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.

Key Points: 
  • Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.
  • Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD.
  • Based on application, the intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.
  • Based on distribution channel, the intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others.

GBS|CIDP Foundation Launches Campus Plasma Awareness Campaign

Retrieved on: 
Tuesday, October 11, 2022
Caregiver, Peripheral nervous system, Plasma, Fatigue, Crystal, Education, Volunteering, Foundation, Patient, IG, Social consciousness, Research, Program, CIDP, Multimedia, Student, Industry, Weakness, Awareness, Guillain–Barré syndrome, GBS, MMN, Paralysis, Multifocal motor neuropathy, Travel, Chronic inflammatory demyelinating polyneuropathy, View, Sintering, Pharmaceutical industry, Antibody

CONSHOHOCKEN, Pa., Oct. 11, 2022 /PRNewswire/ -- The GBS|CIDP Foundation International is committed to raising awareness about the importance of source plasma, the basic element used to produce Immunoglobulin (IG) therapy.

Key Points: 
  • CONSHOHOCKEN, Pa., Oct. 11, 2022 /PRNewswire/ -- The GBS|CIDP Foundation International is committed to raising awareness about the importance of source plasma, the basic element used to produce Immunoglobulin (IG) therapy.
  • It takes hundreds of plasma donations to treat a single CIDP patient for a year, and the Foundation estimates about 30,000 CIDP patients in the United States.
  • In an effort to increase awareness of the need for source plasma, the Foundation is pleased to announce the launch of Project Plasma, a sweeping outreach program aimed at helping college students learn more about plasma donation.
  • Project Plasma is anchored around a toolkit that students can utilize to organize their own plasma awareness drives around their college campuses, potentially as a way to increase community service hours, fulfill a humanitarian need for a class, or to inspire social consciousness on campus.

Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

Retrieved on: 
Saturday, September 10, 2022
Time, NASDAQ, Survival, SCC, Securities Act of 1933, Nausea, Histology, Principal, Guillain–Barré syndrome, GEJ, Adenocarcinoma, Securities Exchange Act of 1934, Oncology, Chain reaction, Congress, Cancer, San Francisco, Cytokine release syndrome, AC, SEC, Nasdaq, Monocyte, European Society for Medical Oncology, Vomiting, Adoption, CD8, Therapy, Drug Quality and Security Act, GLOBE, University of California, San Francisco, Radiation, ESMO, Safety, B cell, CD40, CD4, MPR, Patient, Tumor microenvironment, Medicine, Neoplasm, Perception, SAN, Squamous cell carcinoma, University, Dysphagia, Pharmaceutical industry, Medical imaging, Residential care, Vaccine

Encouraging pathologic complete response (pCR) rates were observed in patients with both adenocarcinoma (AC) and squamous cell carcinoma (SCC).

Key Points: 
  • Encouraging pathologic complete response (pCR) rates were observed in patients with both adenocarcinoma (AC) and squamous cell carcinoma (SCC).
  • These data were featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.
  • The pathologic complete response rates, an important predictor of survival, compared favorably to historical pCR rates with standard of care treatment alone.
  • Moreover, our study demonstrates that sotiga was able to be safely added to concurrent chemotherapy plus radiation.

Global Central Nervous System Partnering Deals Directory 2022: Trends, Players and Financials for 1,700+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Health, Other Health, Parkinson's disease, Restless legs syndrome, Disease, CNS, Directory, Technology, Dizziness, SEC, Finance, Chapter Four, Multiple sclerosis, Chapter Five, Central nervous system, Chapter Three, Haemophilus influenzae, Restless, Guillain–Barré syndrome, Review, Stroke, Contract, Traumatic brain injury, Amyotrophy, Players, Bacteria, Peripheral neuropathy, Weakness, Chapter Six, Cerebral palsy, Chapter One, Chapter Two, Vertigo, Hyperlink, Migraine, Peripheral nervous system, Spinal cord, Creutzfeldt–Jakob disease, Headache, Mycobacterium tuberculosis, Sclerosis (medicine), TB, A-Z, Pharmaceutical industry, Bank, Risk management, Petroleum, Nausea, Stuttering, Fibromyalgia, Meningitis, Epilepsy, Paralysis, Neuralgia, Pain, Haemophilus

The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.

Key Points: 
  • The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2015.
  • Global Central Nervous System Partnering 2015 to 2022 includes:
    In Global Central Nervous System Partnering 2015 to 2022, available deals and contracts are listed by: